Hepion Pharmaceuticals

US: HEPA

$32.9m market cap

$3.65 last close

Hepion Pharmaceuticals is a clinical stage biopharmaceutical company focused on developing therapeutics for chronic liver disease. The company’s lead asset is CRV431, a cyclophilin inhibitor being developed for the treatment of NASH.

Investment summary

Hepion continues to make progress with the addition of another dose cohort (375mg) to the ongoing CRV431 Phase I clinical trial since dose-limiting side effects were not yet observed at doses up to 300mg. The company also announced preclinical data stating that CRV431 demonstrated anti-fibrotic effects on kidney fibrosis.

Y/E Dec
Revenue (US$m)
EBITDA (US$m)
PBT (US$m)
EPS (c)
P/E (x)
P/CF (x)
2018A 0.0 (14.3) (9.8) (5587.00) N/A N/A
2019A 0.0 (7.7) (7.9) (432.00) N/A N/A
2020E 0.0 (15.0) (15.0) (179.00) N/A N/A
2021E 0.0 (11.4) (11.4) (133.00) N/A N/A
Industry outlook

There currently are no approved medications for NASH, but a large number of programs in development. Fatty liver disease affects 20% of US and European populations, and 20% of these are expected to progress to NASH. We expect CRV431 to be marketed for severe cases (F2 and F4), which we estimate has a market of 1.4m in the US and Europe.

Last updated on 09/07/2020
Sector
Healthcare
Share price graph
Balance sheet
Forecast net cash (US$m) 13.5
Forecast gearing ratio (%) N/A
Price performance
%
1m
3m
12m
Actual 60.1 137.0 (2.4)
Relative* 62.9 109.8 (7.7)
52-week high/low US$7.0/US$1.1
*% relative to local index
Key management
Robert Foster CEO
John Cavan FD